Tratamiento antigripal

fármacos actualmente utilizados y nuevos agentes en desarrollo

Translated title of the contribution: Anti-Influenza Treatment: Drugs Currently Used and Under Development

Luciano Amarelle, Emilia Lecuona, Jacob I Sznajder*

*Corresponding author for this work

Research output: Contribution to journalShort survey

13 Citations (Scopus)

Abstract

Influenza is a very common contagious disease that carries significant morbidity and mortality. Treatment with antiviral drugs is available, which if administered early, can reduce the risk of severe complications. However, many virus types develop resistance to those drugs, leading to a notable loss of efficacy. There has been great interest in the development of new drugs to combat this disease. A wide range of drugs has shown anti-influenza activity, but they are not yet available for use in the clinic. Many of these target viral components, which others are aimed at elements in the host cell which participate in the viral cycle. Modulating host components is a strategy which minimizes the development of resistance, since host components are not subject to the genetic variability of the virus. The main disadvantage is the risk of treatment-related side effects. The aim of this review is to describe the main pharmacological agents currently available and new drugs in the pipeline with potential benefit in the treatment of influenza.

Original languageSpanish
Pages (from-to)19-26
Number of pages8
JournalArchivos de Bronconeumologia
Volume53
Issue number1
DOIs
StatePublished - Jan 1 2017

Fingerprint

Human Influenza
Pharmaceutical Preparations
Viruses
Viral Structures
Antiviral Agents
Pharmacology
Morbidity
Mortality

Keywords

  • Drugs
  • Influenza
  • Influenza virus
  • Treatment

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

@article{8c06e8b5065f458fa9906a22e1c26b84,
title = "Tratamiento antigripal: f{\'a}rmacos actualmente utilizados y nuevos agentes en desarrollo",
abstract = "Influenza is a very common contagious disease that carries significant morbidity and mortality. Treatment with antiviral drugs is available, which if administered early, can reduce the risk of severe complications. However, many virus types develop resistance to those drugs, leading to a notable loss of efficacy. There has been great interest in the development of new drugs to combat this disease. A wide range of drugs has shown anti-influenza activity, but they are not yet available for use in the clinic. Many of these target viral components, which others are aimed at elements in the host cell which participate in the viral cycle. Modulating host components is a strategy which minimizes the development of resistance, since host components are not subject to the genetic variability of the virus. The main disadvantage is the risk of treatment-related side effects. The aim of this review is to describe the main pharmacological agents currently available and new drugs in the pipeline with potential benefit in the treatment of influenza.",
keywords = "Drugs, Influenza, Influenza virus, Treatment",
author = "Luciano Amarelle and Emilia Lecuona and Sznajder, {Jacob I}",
year = "2017",
month = "1",
day = "1",
doi = "10.1016/j.arbr.2016.11.020",
language = "Spanish",
volume = "53",
pages = "19--26",
journal = "Archivos de Bronconeumologia",
issn = "0300-2896",
publisher = "Ediciones Doyma, S.L.",
number = "1",

}

Tratamiento antigripal : fármacos actualmente utilizados y nuevos agentes en desarrollo. / Amarelle, Luciano; Lecuona, Emilia; Sznajder, Jacob I.

In: Archivos de Bronconeumologia, Vol. 53, No. 1, 01.01.2017, p. 19-26.

Research output: Contribution to journalShort survey

TY - JOUR

T1 - Tratamiento antigripal

T2 - fármacos actualmente utilizados y nuevos agentes en desarrollo

AU - Amarelle, Luciano

AU - Lecuona, Emilia

AU - Sznajder, Jacob I

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Influenza is a very common contagious disease that carries significant morbidity and mortality. Treatment with antiviral drugs is available, which if administered early, can reduce the risk of severe complications. However, many virus types develop resistance to those drugs, leading to a notable loss of efficacy. There has been great interest in the development of new drugs to combat this disease. A wide range of drugs has shown anti-influenza activity, but they are not yet available for use in the clinic. Many of these target viral components, which others are aimed at elements in the host cell which participate in the viral cycle. Modulating host components is a strategy which minimizes the development of resistance, since host components are not subject to the genetic variability of the virus. The main disadvantage is the risk of treatment-related side effects. The aim of this review is to describe the main pharmacological agents currently available and new drugs in the pipeline with potential benefit in the treatment of influenza.

AB - Influenza is a very common contagious disease that carries significant morbidity and mortality. Treatment with antiviral drugs is available, which if administered early, can reduce the risk of severe complications. However, many virus types develop resistance to those drugs, leading to a notable loss of efficacy. There has been great interest in the development of new drugs to combat this disease. A wide range of drugs has shown anti-influenza activity, but they are not yet available for use in the clinic. Many of these target viral components, which others are aimed at elements in the host cell which participate in the viral cycle. Modulating host components is a strategy which minimizes the development of resistance, since host components are not subject to the genetic variability of the virus. The main disadvantage is the risk of treatment-related side effects. The aim of this review is to describe the main pharmacological agents currently available and new drugs in the pipeline with potential benefit in the treatment of influenza.

KW - Drugs

KW - Influenza

KW - Influenza virus

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85026249393&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026249393&partnerID=8YFLogxK

U2 - 10.1016/j.arbr.2016.11.020

DO - 10.1016/j.arbr.2016.11.020

M3 - Short survey

VL - 53

SP - 19

EP - 26

JO - Archivos de Bronconeumologia

JF - Archivos de Bronconeumologia

SN - 0300-2896

IS - 1

ER -